122 related articles for article (PubMed ID: 10487284)
1. Limited sampling model for area-under-the-curve monitoring in pediatric patients receiving either Sandimmune or Neoral cyclosporin A oral formulations.
Medeiros M; Pérez-Urizar J; Muñoz R; Castañeda-Hernández G
Pediatr Transplant; 1999 Aug; 3(3):225-30. PubMed ID: 10487284
[TBL] [Abstract][Full Text] [Related]
2. A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation.
Meier-Kriesche HU; Kaplan B; Brannan P; Kahan BD; Portman RJ
Ther Drug Monit; 1998 Aug; 20(4):401-7. PubMed ID: 9712465
[TBL] [Abstract][Full Text] [Related]
3. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?
Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G
Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945
[TBL] [Abstract][Full Text] [Related]
4. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
5. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration.
Gaspari F; Anedda MF; Signorini O; Remuzzi G; Perico N
J Am Soc Nephrol; 1997 Apr; 8(4):647-52. PubMed ID: 10495795
[TBL] [Abstract][Full Text] [Related]
6. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
[TBL] [Abstract][Full Text] [Related]
7. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients.
Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R
Pediatr Transplant; 1999 Nov; 3(4):282-7. PubMed ID: 10562972
[TBL] [Abstract][Full Text] [Related]
8. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
9. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of two oral formulations of cyclosporin A in uremic children before renal transplantation.
Medeiros M; Gómez AC; Urizar JP; Campos-Sepúlveda AE; Saldaña IM; Ramírez LE; Romero NB; Velásquez JL; Castañeda-Hernández G; Muñoz R
Pediatr Transplant; 1998 May; 2(2):145-9. PubMed ID: 10082447
[TBL] [Abstract][Full Text] [Related]
11. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients.
Meier-Kriesche HU; Alloway R; Gaber AO; Canafax DM; Kaplan B
J Clin Pharmacol; 1999 Feb; 39(2):166-71. PubMed ID: 11563409
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
Schädeli F; Marti HP; Frey FJ; Uehlinger DE
Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
[TBL] [Abstract][Full Text] [Related]
13. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
Strong DK; Lai A; Primmett D; White CT; Lirenman DS; Carter JE; Hurley RM; Virji M; Ensom MH
Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
van Mourik ID; Thomson M; Kelly DA
Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
[TBL] [Abstract][Full Text] [Related]
15. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group.
Marsh CL
Ther Drug Monit; 1999 Feb; 21(1):27-34. PubMed ID: 10051051
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients.
Dotti G; Gaspari F; Caruso R; Perico N; Remuzzi G; Barbui T; Rambaldi A
Haematologica; 2001 Mar; 86(3):311-5. PubMed ID: 11255279
[TBL] [Abstract][Full Text] [Related]
17. Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra.
Terrill CJ; Lill J; Somerville KT; Sherbotie JR
J Ren Nutr; 2003 Jan; 13(1):26-30. PubMed ID: 12563620
[TBL] [Abstract][Full Text] [Related]
18. Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients.
Tokui K; Kimata T; Uchida K; Yuasa H; Hayashi Y; Itatsu T; Nabeshima T
Ther Drug Monit; 2004 Jun; 26(3):287-94. PubMed ID: 15167630
[TBL] [Abstract][Full Text] [Related]
19. A polycaprolactone nanoparticle formulation of cyclosporin-A improves the prediction of area under the curve using a limited sampling strategy.
Molpeceres J; Chacón M; Guzmán M; Berges L; del Rosario Aberturas M
Int J Pharm; 1999 Sep; 187(1):101-13. PubMed ID: 10502617
[TBL] [Abstract][Full Text] [Related]
20. Decreased oral availability of cyclosporin A at second administration in humans.
Lee YJ; Chung SJ; Shim CK
Br J Clin Pharmacol; 1997 Oct; 44(4):343-5. PubMed ID: 9354308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
